Author(s): Descamps G, GomezBougie P, Venot C, Moreau P, Bataille R,
Abstract Share this page
Abstract The humanised form of an antagonistic anti-IGF-1R mAb (AVE1642) selectively inhibits the growth of CD45(neg) myeloma cells. AVE1642 strongly increased bortezomib-induced apoptosis, correlated with an increase of Noxa expression. These results support the therapeutic use of anti-IGF-1R/bortezomib in CD45(neg) Myeloma patients, particularly those with the most aggressive form, t(4,14).
This article was published in Br J Cancer
and referenced in Journal of Clinical & Cellular Immunology